Results 241 to 250 of about 93,504 (350)

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists. [PDF]

Cureus
Okunlola AO, Kolawole O, Otabor E, Hassan A, Hamilton M, Alomari L, Lam J, Idowu AB.   +7 more
europepmc   +1 more source

Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease [PDF]

, 2005
Atsushi Sato, Kenshi Hayashi, T Saruta
openalex   +1 more source

From Synaptic Plasticity and Critical Periods to Social Behavior and Stress: Getting to, and Staying in, CA2

Hippocampus, Volume 36, Issue 1, January 2026.
ABSTRACT Hippocampal Area CA2, with some exceptions, had long been neglected in in vivo studies, due largely to its small size, and in in vitro studies because of its general similarity to CA3 and CA1. Increasing evidence showing that CA2 was molecularly distinct led to the increased appreciation of CA2 as a separate region, and as such, that it likely
Serena M. Dudek
wiley   +1 more source

Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone. [PDF]

J Endocr Soc
Sbrocchi AM, Kinnett K, Lautatzis ME, McMillan HJ, Selby KA, Veerapandiyan A, Weber DR, Apkon S, Bharucha-Goebel DX, Bharill S, Bansal S, Clemens PR, Fiscaletti M, Halloun R, Lam C, Merchant N, McAdam L, Nasomyont N, Nicolau S, Ochoa Molina MF, Phung K, Rutter MM, Scavina M, Surampudi PN, Tamaroff J, Tian C, Ward LM, Wood CL, Wong SC, Ahmet A, OPTIMIZE DMD Consortium .   +30 more
europepmc   +1 more source

Need to Revisit Heart Failure Treatment Guidelines for Hyperkalaemia Management During the Use of Mineralocorticoid Receptor Antagonists [PDF]

, 2018
Javed Butler, Shilpa Vijayakumar, Bertram Pitt   +2 more
openalex   +1 more source

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hazel J. Hunt, Kirsteen M. Donaldson, Jeevan R. Kunta, Joseph M. Custodio   +3 more
wiley   +1 more source

Overactivation of the Aldosterone^|^frasl;Mineralocorticoid Receptor System in Metabolic Syndrome and its Implication in Cardiac and Kidney Injury

, 2012
Miki Nagase
openalex   +2 more sources

Case Report: Compound Heterozygous SCNN1B Mutations Causing Pseudohypoaldosteronism Type 1B2 in Neonatal Twins

Molecular Genetics &Genomic Medicine, Volume 14, Issue 1, January 2026.
First Chinese neonatal cases of systemic PHA1B from novel compound‐heterozygous SCNN1B variants (c.585+2T>C; c.1544T>C) presented with life‐threatening hyperkalemia and hyponatremia unresponsive to steroids. Early genetic testing enabled targeted sodium supplementation and potassium‐binding therapy, normalizing electrolytes and underscoring SCNN1B ...
Zhiping Wang, Lijuan Long, Hongjuan Bi
wiley   +1 more source

First European case of Geller syndrome complicated with hypokalemic nephropathy: A case report and literature review. [PDF]

Metabol Open
Gavriilidis E, Antoniadou C, Dimopoulou G, Papadimitriou E, Bakola SA, Papagoras C, Skendros P, Tsilingiris D.   +7 more
europepmc   +1 more source

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis

Chien‐Wei Huang, Tse‐Ying Huang, Yafei Yang, Li‐Yang Chang, Yu‐Kang Tu, Vin‐Cent Wu, Jui‐Yi Chen   +6 more
openalex   +1 more source